LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

The global Clinical Trial Services Market, valued at US$60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9% ...

LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year, putting the company on track to meet its ...

An Ipsos survey commissioned by LEO Pharma Inc. reveals dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 ...

2 The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for ...